To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars Adv Ther (2018) 35:749–753 https://doi.org/10.1007/s12325-018-0719-8 COMMENTARY To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars Mourad F. Rezk Burkhard Pieper Received: April 16, 2018 / Published online: June 5, 2018 Springer Healthcare Ltd., part of Springer Nature 2018 Abstract: In addition to the general clinical clinical trials, and that this effect may nega- benefit offered, biosimilars may not only gen- tively affect acceptance in patients switching erate savings for healthcare budgets but also from an originator product to a biosimilar. improve patient access to biologic products. Awareness of the potential for the nocebo effect Since the first biosimilar was approved in Eur- and adoption of enhanced communication ope in 2006, a further 36 different biosimilar techniques may be useful in mitigating the drugs have been approved for several indica- nocebo effect. Effective healthcare profes- tions. Despite the wealth of experience gained sional–patient dialogue is key in transferring and the reported data supporting the use of confidence to the patient, and has been shown biosimilars, both in naı¨ve and biologic-experi- to reduce nocebo effects in patients when enced patients, some healthcare professionals switching from an originator to a biosimilar. continue to express doubt http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars

Loading next page...
 
/lp/springer_journal/to-see-or-nosee-the-debate-on-the-nocebo-effect-and-optimizing-the-use-ko9ca5LRCD
Publisher
Springer Healthcare
Copyright
Copyright © 2018 by Springer Healthcare Ltd., part of Springer Nature
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-018-0719-8
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2018) 35:749–753 https://doi.org/10.1007/s12325-018-0719-8 COMMENTARY To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars Mourad F. Rezk Burkhard Pieper Received: April 16, 2018 / Published online: June 5, 2018 Springer Healthcare Ltd., part of Springer Nature 2018 Abstract: In addition to the general clinical clinical trials, and that this effect may nega- benefit offered, biosimilars may not only gen- tively affect acceptance in patients switching erate savings for healthcare budgets but also from an originator product to a biosimilar. improve patient access to biologic products. Awareness of the potential for the nocebo effect Since the first biosimilar was approved in Eur- and adoption of enhanced communication ope in 2006, a further 36 different biosimilar techniques may be useful in mitigating the drugs have been approved for several indica- nocebo effect. Effective healthcare profes- tions. Despite the wealth of experience gained sional–patient dialogue is key in transferring and the reported data supporting the use of confidence to the patient, and has been shown biosimilars, both in naı¨ve and biologic-experi- to reduce nocebo effects in patients when enced patients, some healthcare professionals switching from an originator to a biosimilar. continue to express doubt

Journal

Advances in TherapySpringer Journals

Published: Jun 5, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off